According to Anixa Biosciences's latest financial reports the company's current revenue (TTM) is $0.21 M. In 2023 the company made a revenue of $0.21 M an increase over the years 2022 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2024 (TTM) | $0.21 M | 0% |
2023 | $0.21 M | |
2022 | N/A | -100% |
2021 | $0.51 M | |
2020 | N/A | -100% |
2019 | $0.25 M | -77.53% |
2018 | $1.11 M | 206.9% |
2017 | $0.36 M | 20.83% |
2016 | $0.3 M | -96.76% |
2015 | $9.25 M | 152.36% |
2014 | $3.66 M | 848.31% |
2013 | $0.38 M | -59.17% |
2012 | $0.94 M | -5.59% |
2011 | $1 M | 37.3% |
2010 | $0.73 M | -30.79% |
2009 | $1.05 M | -48.83% |
2008 | $2.06 M | 323.77% |
2007 | $0.48 M | -4.29% |
2006 | $0.5 M | 15.66% |
2005 | $0.43 M | -11.06% |
2004 | $0.49 M | 102.46% |
2003 | $0.24 M | -95.29% |
2002 | $5.18 M | 206.77% |
2001 | $1.69 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |